Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:13:00.033Z.
Calculation as of: 2026-10-06T16:13:00.033Z.
Quote observation: 2026-10-06T16:10:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 85bde4aa0a662304b106d2bd805683c4a4a85ed0eecab472c1d88190f6ac555e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2025-08-12.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
EV/EBIT RATIO AVG TTM
N/A
EV/EBIT RATIO AVG 3Y
N/A
EV/EBIT RATIO AVG 5Y
N/A
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$1.46B
EV/EBIT Ratio
10.04x
TTM Avg
25.95x
3Y Avg
23.59x
5Y Avg
24.10x
Market Cap
$1.43B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.42B
EV/EBIT Ratio
29.81x
TTM Avg
29.70x
3Y Avg
32.28x
5Y Avg
57.69x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | $1.45B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.47B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 10.04x | 25.95x | 23.59x | 24.10x |
| Certara, Inc. (CERT)vs › | $1.46B | 206.41x | 79.44x | 108.81x | 130.77x |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 11.67x | 36.76x | 36.76x | 36.50x |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.48B | N/A | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.42B | 29.81x | 29.70x | 32.28x | 57.69x |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/EBIT RATIO |
|---|---|
| 2025-08-12 | 6.64x |
| 2025-08-11 | 6.40x |
| 2025-08-08 | 6.11x |
| 2025-08-07 | 6.27x |
| 2025-08-06 | 7.08x |
| 2025-08-05 | 7.31x |
| 2025-08-04 | 7.96x |
| 2025-08-01 | 7.65x |
| 2025-07-31 | 7.52x |
| 2025-07-30 | 8.17x |
| 2025-07-29 | 8.38x |
| 2025-07-28 | 8.92x |
| 2025-07-25 | 9.33x |
| 2025-07-24 | 9.00x |
| 2025-07-23 | 10.04x |
| 2025-07-22 | 9.43x |
| 2025-07-21 | 9.19x |
| 2025-07-18 | 10.16x |
| 2025-07-17 | 9.53x |
| 2025-07-16 | 8.84x |
| 2025-07-15 | 8.62x |
| 2025-07-14 | 8.38x |
| 2025-07-11 | 7.78x |
| 2025-07-10 | 8.30x |
| 2025-07-09 | 7.81x |
| 2025-07-08 | 7.79x |
| 2025-07-07 | 5.22x |
| 2025-07-03 | 4.68x |
| 2025-07-02 | 5.00x |
| 2025-07-01 | 4.82x |
| 2025-06-30 | 5.36x |
| 2025-06-27 | 5.23x |
| 2025-06-26 | 5.77x |
| 2025-06-25 | 4.61x |
| 2025-06-24 | 3.66x |
| 2025-06-23 | 4.01x |
| 2025-06-20 | 4.40x |
| 2025-06-18 | 4.47x |
| 2025-06-17 | 5.46x |
| 2025-06-16 | 6.26x |
| 2025-06-13 | 6.34x |
| 2025-06-12 | 6.47x |
| 2025-06-11 | 5.80x |
| 2025-06-10 | 5.88x |
| 2025-06-09 | 5.83x |
| 2025-06-06 | 5.93x |
| 2025-06-05 | 6.29x |
| 2025-06-04 | 6.75x |
| 2025-06-03 | 6.57x |
| 2025-06-02 | 5.21x |
| 2025-05-30 | 3.38x |
| 2025-05-29 | 5.27x |
| 2025-05-28 | 4.67x |
| 2025-05-27 | 4.42x |
| 2025-05-23 | 3.62x |
| 2025-05-22 | 3.52x |
| 2025-05-21 | 3.83x |
| 2025-05-20 | 3.47x |
| 2025-05-19 | 3.11x |
| 2025-05-16 | 2.72x |
| 2025-05-15 | 2.72x |
| 2025-05-14 | 3.94x |
| 2025-05-13 | 4.54x |
| 2025-05-12 | 4.75x |
| 2025-05-09 | 4.36x |
| 2025-05-08 | 4.67x |
| 2025-05-07 | 4.26x |
| 2025-05-06 | 3.97x |
| 2025-05-05 | 4.97x |
| 2025-05-02 | 5.30x |
| 2025-05-01 | 5.10x |
| 2025-04-30 | 4.08x |
| 2025-04-29 | 3.73x |
| 2025-04-28 | 3.42x |
| 2025-04-25 | 3.29x |
| 2025-04-24 | 2.90x |
| 2025-04-23 | 4.31x |
| 2025-04-22 | 4.54x |
| 2025-04-21 | 3.99x |
| 2025-04-17 | 3.44x |
| 2025-04-16 | 3.27x |
| 2025-04-15 | 3.21x |
| 2025-04-14 | 3.51x |
| 2025-04-11 | 3.00x |
| 2025-04-10 | 2.82x |
| 2025-04-09 | 3.11x |
| 2025-04-08 | 2.80x |
| 2025-04-07 | 3.83x |
| 2025-04-04 | 3.94x |
| 2025-04-03 | 4.13x |
| 2025-04-02 | 4.93x |
| 2025-04-01 | 4.57x |
| 2025-03-31 | 6.40x |
| 2025-03-28 | 6.68x |
| 2025-03-27 | 6.58x |
| 2025-03-26 | 6.23x |
| 2025-03-25 | 6.83x |
| 2025-03-24 | 6.98x |
| 2025-03-21 | 6.49x |
| 2025-03-20 | 7.05x |
| 2025-03-19 | 7.17x |
| 2025-03-18 | 7.12x |
| 2025-03-17 | 6.73x |
| 2025-03-14 | 6.39x |
| 2025-03-13 | 6.60x |
| 2025-03-12 | 6.60x |
| 2025-03-11 | 6.55x |
| 2025-03-10 | 6.93x |
| 2025-03-07 | 7.08x |
| 2025-03-06 | 6.89x |
| 2025-03-05 | 6.99x |
| 2025-03-04 | 6.97x |
| 2025-03-03 | 6.42x |
| 2025-02-28 | 7.24x |
| 2025-02-27 | 7.57x |
| 2025-02-26 | 6.87x |
| 2025-02-25 | 6.10x |
| 2025-02-24 | 6.27x |
| 2025-02-21 | 7.14x |
| 2025-02-20 | 7.19x |
| 2025-02-19 | 7.46x |
| 2025-02-18 | 7.62x |
| 2025-02-14 | 7.08x |
| 2025-02-13 | 6.62x |
| 2025-02-12 | 7.06x |
| 2025-02-11 | 7.40x |
| 2025-02-10 | 7.73x |
| 2025-02-07 | 8.02x |
| 2025-02-06 | 7.76x |
| 2025-02-05 | 7.64x |
| 2025-02-04 | 7.93x |
| 2025-02-03 | 9.12x |
| 2025-01-31 | 9.77x |
